After months of rumors, Google introduced its personal smartwatch, known as the Pixel Watch, shall be coming this fall.
Though the tech large has supported smartwatches via its wearable working system and accomplished its acquisition of Fitbit final 12 months, that is Google’s first branded smartwatch. The Pixel Watch can have a round, domed design made with recycled stainless-steel and customizable bands.
Despite the fact that the watch additionally has loads of options not involved with well being monitoring, Rick Osterloh, Google’s senior vp of units and providers, teased the Pixel Watch’s “deep integration” with Fitbit that can embody coronary heart charge and sleep monitoring in addition to exercise metrics customers can measure towards their objectives.
In the meantime, Google is getting into a crowded marketplace for health-tracking wearables, with opponents like Apple, Amazon, Samsung, Withings and Garmin. Fitbit lately landed FDA clearance for its long-awaited photoplethysmography atrial fibrillation (AFib) detection algorithm.
The chatbot presents cognitive behavioral remedy that might reduce despair and nervousness signs and assist customers handle ache to enhance bodily operate.
The Breakthrough Gadgets program permits firms to work with the FDA earlier than advertising and marketing approval. It goals to hurry the event, evaluation and evaluate course of for medical units and mixture merchandise that might present higher remedy for folks with debilitating or life-threatening diseases or circumstances.
“We’re thrilled to realize this significant designation from the FDA and stay up for working carefully with the company to proceed improvement of AI-based cognitive behavioral remedy,” Wysa cofounder and CEO Jo Aggarwal stated in an announcement.
“Our mission is to assist these in want of assist with an at all times obtainable platform, and through these difficult occasions it’s extra essential than ever to supply psychological well being choices.”
Wysa raised $5.5 million in Sequence A funding in Could 2021.
Pear Therapeutics is increasing a program to supply its prescription digital therapeutics via partnerships with telehealth suppliers.
The corporate’s latest associate, QuickMD, will be capable of present eligible sufferers with Pear’s opioid use dysfunction product, reSET-O.
In April, the corporate introduced this system with its first telehealth providing, addition medicine-focused PursueCare.
“Pear is happy to work with telehealth suppliers in offering modern, FDA-authorized therapies that allow round the clock entry to help eligible sufferers of their restoration journey throughout these tough occasions,” Chief Industrial Officer Julia Strandberg stated in an announcement. “After so many unsure months, you will need to meet folks the place they’re and the place they really feel comfy, offering them with entry to the care they want.”